Obesity, in particular, visceral fat accumulation, causes a cluster of hypertension, type 2 diabetes, and dyslipidemia, also referred to as metabolic syndrome. The accumulated disorders induced by visceral fat accumulation lead to cardiovascular disease, which is one of the leading causes of mortality in western countries. Adipose tissue produces and secretes many bioactive molecules, [1] [2] [3] [4] [5] which are known as adipocytokines or adipokines. 3, 6 Dysregulated production of adipocytokines, such as tumor necrosis factor-α (TNF-α), leptin, and plasminogen activator inhibitor type 1, is associated with the pathogenesis of metabolic syndrome and cardiovascular diseases. [1] [2] [3] [4] [5] Adiponectin is almost exclusively expressed in adipose tissue 7, 8 and exists abundantly at the range 3-30 µg/ml in plasma. Interestingly, plasma adiponectin levels are decreased in obese patients, particularly those with excess visceral fat, and its plasma levels are inversely correlated with visceral adiposity. 9, 10 Low concentration of adiponectin, so-called hypoadiponectinemia, is closely associated with obesityrelated diseases including hypertension, type 2 diabetes, and cardiovascular disease. [11] [12] [13] [14] Numerous experimental studies have shown that adiponectin displays a variety of protective actions on obesity-induced pathological conditions, including hypertension, insulin resistance, hepatic steatosis, atherosclerosis, and ischemic heart disease. [15] [16] [17] [18] [19] Furthermore, adiponectin exerts antiatherogenic and anti-inflammatory effects by its ability to act on vascular component cells including endothelial cells and macrophages. [20] [21] [22] [23] [24] [25] [26] In this review, we will focus on the key role of adiponectin in regulating vascular homeostasis.
Adiponectin As A BiomArker For Hypertension
A number of clinical studies have demonstrated the relationship of plasma adiponectin concentration with hypertension. 11, 12, 27, 28 Adamczak et al. showed for the first time that plasma adiponectin levels are significantly lower in patients with essential hypertension compared with those in body mass index-matched normotensive subjects. 11 An inverse correlation is observed between adiponectin concentration and mean systolic and diastolic blood pressure. Similarly, adipo nectin levels are negatively associated with blood pressure in patients with type 2 diabetes and metabolic syndrome. 29 In addition, Iwashima et al. have demonstrated that a hypoadiponectinemia is a risk factor for hypertension independent of insulin resistance and diabetes. 12 Adiponectin has been reported to associate with the progression of hypertension. Chow et al. for the first time demonstrated an inverse relation between plasma adiponectin concentration and the future development of hypertension by prospective analysis of Chinese subjects for 5 years. 30 In this study, 70 normotensive, nondiabetic subjects, who developed hypertension by the end point, were compared with 140 ageand sex-matched subjects who were normotensive during the observed periods. Hypoadiponectinemia at baseline is a strong predictor of future hypertension even after adjusting the confounding factors such as mean blood pressure, C-reactive protein, body mass index, and waist circumference. Subjects with hypoadiponectinemia show three times higher morbidity of future hypertension than those with normal range of adiponectin levels.
Analysis of mutations in human adiponectin gene provides further information about the link between adiponectin and hypertension. Among several single-nucleotide polymorphisms of adiponectin gene, single-nucleotide polymorphism at position 164 (TC genotype of the I164T) has been associated with hypoadiponectinemia and high blood pressure in Japanese population. 12 I164T mutation is also related to metabolic syndrome and coronary heart disease. 31, 32 Hypoadiponectinemia caused by I164T mutation is due, at least in part, to disturbance of secretion of adiponectin into plasma. 33 An experimental study also supports the notion that adiponectin modulates blood pressure. Adiponectin-knockout mice show no phenotype of hypertension under unstressed conditions. However, after high-salt diet feeding, adiponectinknockout mice exhibit significantly higher levels of systolic blood pressure compared with wild-type (WT) mice independent of insulin resistance. 15 Adiponectin replenishment by adenovirus system ameliorates the high-salt diet-induced hypertension of adiponectin-knockout mice. Adenovirusmediated overexpression of adiponectin dramatically reduces the systolic blood pressure in a genetic mouse model of obesity and hypertension. Furthermore, in aldosterone infusion model with uninephrectomy, adiponectin-knockout mice develop higher systolic blood pressure compared with WT mice. 34 Aldosterone-infused adiponectin-knockout mice also show severer left ventricular hypertrophy and pulmonary congestion compared with control mice. Analysis of diastolic heart function by echocardiogram revealed that adiponectin-knockout mice have severe diastolic dysfunction following aldosterone infusion. 34 Thus, adiponectindeficiency contributes to the development of hypertension under conditions of stress.
Collectively, hypoadiponectinemia induced by visceral fat accumulation is highly associated with hypertension.
Adiponectin And endotHeliAl Function
Endothelial dysfunction is an important feature predisposing to vascular disease and is closely associated with obesitylinked complications including hypertension and insulin resistance. 35 Numerous studies have shown that adiponectin is beneficial for endothelial function. Plasma adiponectin level is closely correlated with the vasodilator response to reactive hyperemia in hypertensive patients. 36 Likewise, plasma adiponectin level is positively associated with the forearm blood flow response during reactive hyperemia in apparently healthy men. 37 Furthermore, hypoadiponectinemia has been reported to associate with impaired endothelium-dependent vasodilation of the brachial artery in diabetic patients. 38 In support of these clinical data, adiponectin-knockout mice display impairment of endothelium-dependent vasodilation in response to acetylcholine compared with control mice when fed an atherogenic diet. 36 Endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) are crucial regulators of vascular homeostasis, in particular, endothelial function. 39, 40 Accumulating evidence indicates that adiponectin functions as an endogenous modulator of endothelial-derived NO production. Adiponectin-knockout mice have lower levels of eNOS transcripts in aorta and NO metabolites in plasma as well as higher blood pressure compared with WT mice after high-salt diet feeding. 15 Systemic administration of adiponectin to high salt-fed adiponectinknockout mice lowers the elevated blood pressure and restores the reduced eNOS transcripts in aorta. Of importance, inhibition of NOS reverses the reduction of blood pressure caused by adiponectin in adiponectin-knockout mice. Thus, adiponectin-deficiency participates in salt-sensitive hypertension through modulation of eNOS function.
Nishimura et al. have shown that adiponectin-knockout mice develop exacerbated cerebral ischemia-reperfusion injury with reduced eNOS activation in ischemic brain tissue and decreased NO metabolites in plasma compared with WT mice. 41 Kondo et al. reported that caloric restriction promotes revascularization in response to tissue ischemia through an adiponectin-mediated activation of eNOS. 42 In another article, adiponectin-knockout mice exhibit reduced levels of endothelial NO in the vessel walls. 43 These findings strongly suggest that the favorable actions of adiponectin on vascular response are mediated, at least in part, by its ability to activate eNOS.
A number of in vitro experiments reveal the important role of adiponectin in regulating eNOS activity and NO production. Adiponectin stimulates phosphorylation of eNOS at Ser-1177 in human endothelial cells through its ability to activate AMPactivated protein kinase signaling. 20 Adiponectin also stimulates NO production in vascular endothelial cells through phosphorylation of eNOS 22 (Figure 1) . The stimulatory effects adiponectin ameliorates endothelial cell function through two independent regulatory mechanisms within endothelial cells. adiponectin enhances eNOS activity and subsequent NO production through adipo R1/R2-aMPK signaling. adiponectin stimulates cyclooxygenase-2 (cOX-2) expression and prostaglandin I 2 (PGI 2 ) production through calreticulin (cRT)/cD91-dependent akt signaling pathway. aMPK, aMP-activated protein kinase; eNOS, endothelial nitric oxide synthase; NO, nitric oxide.
of adiponectin on eNOS activity and NO production are shown to be mediated through adiponectin receptors, Adipo R1/R2 and their intracellular adaptor molecule APPL1. 44 In addition, treatment of bovine endothelial cells with globular fragment of adiponectin increases eNOS mRNA and protein expressions, leading to increased production of NO. 45 Thus, these results suggest that hypoadiponectinemia can cause decreased endothelium-derived NO production and subsequent endothelial dysfunction, ultimately contributing to the development of hypertension. In addition to the above-mentioned signaling pathway, adiponectin promotes endothelial cell function through another mechanism. Endothelial cyclooxygenese-2 (COX-2) and its metabolites play an important role in control of vascular functions such as vascular tone and endothelial function. [46] [47] [48] [49] A recent report with mouse genetic experiments shows that adiponectin promotes revascularization in response to tissue ischemia through COX-2-dependent mechanism. 24 Deletion of COX-2 in an endothelial specific manner results in suppression of adiponectin-induced revascularization response in ischemic muscle. In cultured endothelial cells, recombinant adiponectin treatment significantly increases COX-2 expression and promotes endothelial cell function via activation of Akt-dependent COX-2 signaling pathway. Importantly, adiponectin-mediated endothelial cell protection via Akt-COX-2 regulatory axis is largely dependent on the ability of adiponectin to associate with a newly recognized adiponectin-binding protein, calreticulin/ its adaptor protein CD91 on the surface of endothelial cells (Figure 1) . Consistent with these findings, adiponectin promotes a clearance of apoptotic body by macrophages through a calreticulin/CD91-dependent pathway. 50 Furthermore, adiponectin-knockout mice display reduced levels of prostaglandin I synthase mRNA in aorta and circulating prostaglandin I 2 metabolite following high salt feeding. 15 Adiponectin supplementation using adenovirus system restores the reduced levels of prostaglandin I synthase transcript in aorta and prostaglandin I 2 metabolite in plasma in high salt-fed adiponectinknockout mice. These observations indicate that adiponectin improves endothelial cell function, at least in part, through COX-2-prostaglandin I 2 -dependent pathway (Figure 1) .
Taken together, adiponectin protects against endothelial dysfunction via at least two regulatory pathways involving AMP-activated protein kinase-eNOS signaling and COX-2-prostaglandin I 2 signaling within endothelial cells. Future researches with mouse genetic models are needed to dissect the receptor-mediated signaling pathways involved in the vascular protection by adiponectin.
Adiponectin And mAcropHAge Function
A number of epidemiological studies have indicated that plasma adiponectin concentration is negatively correlated with the inflammatory markers C-reactive protein and the proinflammatory cytokine interleukin-6 in blood stream. [51] [52] [53] [54] These observations are in agreement with the experimental data showing the protective properties of adiponectin against inflammation. Adiponectin has been reported to affect the function and phenotype of macrophages by multiple mechanisms, thereby displaying various anti-inflammatory actions. Adiponectin attenuates agonist-stimulated production of a proinflammatory cytokine TNF-α in cultured macrophages, which is accompanied by diminished nuclear factor-κB activation. 55, 56 Because TNF-α acts as a key modulator that associates with the pathology of obesity-linked metabolic and vascular disorders, the salutary actions of adiponectin on various pathological processes may be mediated partly through suppression of TNF-α production in macrophages. In line with this notion, a recent report showed that adiponectin protects against ischemia-induced vascular injury in retina via modulation of TNF-α inflammatory response. 57 One of the crucial steps in atherogenesis is adherence of monocytes to damaged endothelial cells and subsequent monocyte-to-macrophage transformation. Adiponectin suppresses adherence of monocytes to TNF-α-stimulated endothelial cells by inhibiting expression of adhesion molecules. 4, 14 Adiponectin also suppresses expression of class A scavenger receptor in human macrophages and prevents transformation of macrophages to foam cells. 58 Consistent with these in vitro findings, overexpression of adiponectin protects against the development of atherosclerosis in a mouse model of atherosclerosis. 18, 59 Furthermore, adiponectin promotes the efficient removal of apoptotic debris from the body by macrophages through a cell surface calreticulin/CD91 system on macrophage, thereby preventing inflammation and immune system dysfunction. 50 Recent evidence suggests that adipose tissue macrophages play an important role in the chronic inflammatory state and metabolic dysfunction associated with obesity. 60, 61 Interestingly, macrophages from fat tissue of lean subjects express markers of the M2 or "alternatively activated" macrophage, whereas obesity leads to a reduction of M2 markers and an increase of genes associated with the M1 or " classically activated" macrophage 62 (Figure 2) . M1 macrophage polarization causes inflammation and tissue destruction, whereas the M2 macrophage is believed to display an anti-inflammatory phenotype and rather confer wound repair and vascular protection (Figure 2) .
A recent study has shown that peritoneal macrophages and stromal vascular fractions (SVF), which include macrophages and vascular components except for adipocytes, isolated from adiponectin-knockout mice display an activated M1 phenotype. 25 Conversely, adenovirus-mediated systemic delivery of adiponectin promotes expression of arginase-1, a well-known M2 marker, in peritoneal macrophages and SVF in WT and adiponectin-knockout mice. In vitro cultured experiments also show that treatment of mouse peritoneal macrophages and SVF with recombinant adiponectin protein leads to upregulation of M2 markers including arginase-1, macrophage galactose N-acetyl-galactosamine specific lectin-1 (Mgl-1) and interleukin-10. In contrast, treatment with adiponectin protein attenuates expression of M1 markers including TNF-α, interleukin-6, and monocyte chemotactic protein-1 in cultured mouse macrophage and SVF. The elevation of M2 markers and suppression of M1 markers following adiponectin treatment are also found in cultured human monocyte-derived macrophages and SVF (Figure 2) . Therefore, it is conceivable that adiponectin ameliorates vascular disorders including endothelial dysfunction by its ability to promote macrophage polarization toward the anti-inflammatory phenotype. However, the molecular mechanism by which adiponectin regulates macrophage behavior has not been fully understood. Future studies are necessary to elucidate the adiponectin signaling pathways that are involved in changes in macrophage function and phenotype.
Adiponectin And renin-Angiotensin system (rAs)
The RAS plays a crucial role in cardiovascular homeo stasis by regulating blood pressure and vascular function. 63, 64 Accumulating evidence indicates the important role of RAS in regulation of adiponectin production. Watanabe et al. showed that an antihypertensive drug angiotensin II type 1 receptor blocker (ARB) losartan treatment for 3 months increases plasma adiponectin concentration in patients with essential hypertension. In contrast, treatment with a calcium blocker, amlodipine, has no effect on adiponectin levels in this population. 65 Similarly, losartan treatment for 6 months increases serum adiponectin levels in hypertensive patients with metabolic syndrome. 66 Furthermore, plasma adiponectin levels are significantly increased after 8 weeks of treatment with an ARB telmisartan in patients with essential hypertension. 67 It has also been shown that both telmisartan and another ARB irbesartan increase circulating adiponectin levels in patients with insulin resistance and hypertension. 68 Therefore, inhibition of angiotensin II type 1 receptor-mediated signaling appears to lead to elevation of adiponectin levels in hypertensive subjects.
Conversely, administration of angiotensin II to rats fed with a high-fructose diet significantly decreases plasma adipo nectin levels. 69 Interestingly, plasma adiponectin concentration decreases before the blood pressure increase after angiotensin II infusion. Angiotensin II is known to stimulate generation of reactive oxygen species. Furukawa et al. demonstrated that the increased reactive oxygen species cause dysregulation of adipocytokines including reduced levels of adiponectin and that hydrogen peroxide, one of reactive oxygen species, inhibits adiponectin expression in adipose tissue. 70 Thus, activation of RAS reduces adiponectin production partly through enhancement of reactive oxygen species generation. To support this hypothesis, another ARB olmesartan has been shown to restore decreased level of adiponectin in obese animals, which is accompanied by decrease in oxidative stress in adipose tissue. 71 Benson et al. have shown that telmisartan functions to promote peroxisome proliferator-activated receptor-γ (PPAR-γ) activity as a partial agonist for PPAR-γ. 72 Treatment of 3T3-L1 adipocytes with telmisartan results in upregulation of aP2 and CD36, which are target molecules of PPAR-γ. The administration of PPAR-γ ligands, thiazolidinediones, has been reported to robustly increase the plasma adiponectin concentrations in human and mouse studies. 73 Thiazolidinedione treatment has been shown to enhance expression and secretion of adiponectin in cultured adipocytes. [73] [74] [75] [76] [77] Therefore, PPAR-γ activation by ARBs could be another mechanism of adiponectin upregulation by these agents. 78 Several clinical studies have demonstrated that, in addition to blood pressure-lowering effects, ARBs have various beneficial actions including improvement of glucose and lipid metabolism and vascular function. In a double-blinded randomized trial in patients with essential hypertension, losartan-treated groups exhibit significantly lower new-onset diabetes and stroke compared to atenolol during mean 4.8-year follow-up time. 79 Valsaltan, another ARB, also reduces new-onset type 2 diabetes in nondiabetic hypertensive patients compared with amlodipine. 80, 81 Telmisartan treatment decreases total and low-density lipoprotein cholesterol levels and hemoglobin A 1c in patients with essential hypertension. 82 In addition, telmisartan improves the pulse-wave velocity accompanying with a decreased levels of asymmetric dimethylarginine, an endogenous eNOS inhibitor produced by vascular endothelial cells. 82 Considering the protective actions of adiponectin on metabolic syndrome, multiple functions by ARBs could be attributed to induction of adiponectin. Collectively, these findings suggest that adiponectin upregulation by RAS inhibition is beneficial for not only hypertension but also various metabolic and vascular diosorders.
conclusion
Adiponectin functions as an important adipocytokine linking between adipose tissue and the vasculature. Adiponectin directly acts on vascular endothelial cells and exerts salutary effects on endothelial function through eNOS-dependent and COX-2-dependent regulatory mechanisms. Adiponectin can serve as a regulator of macrophage function and favor anti-inflammatory phenotype in macrophages, potentially contributing to vascular protective properties. Clinical and experimental studies indicate the causal relationship between hypoadiponectinemia and hypertension. Blockade of angiotensin II type 1 receptor leads to elevation of circulating adiponectin levels, which could confer the beneficial pleiotropic effects of ARBs including improvement of metabolic and vascular function beyond antihypertensive actions. Thus, the therapeutic strategies that enhance adiponectin production or action have potential utility for prevention or treatment of obesity-related vascular dysfunction such as hypertension. Taken together, future studies are required to elucidate the molecular and cellular mechanisms of adiponectin regulation and function in more detail for comprehensive understanding of the pathogenesis of metabolic syndrome.
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